[HTML][HTML] Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease
L Di Villeneuve, IL Souza, FDS Tolentino… - Frontiers in …, 2020 - frontiersin.org
Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
G Schvartsman, SA Peng, G Bis, JJ Lee… - Lung Cancer, 2017 - Elsevier
Introduction Exploratory analysis of clinical trials in various tumor types have demonstrated
potential improvements in overall response rate (ORR) to chemotherapy after exposure to …
potential improvements in overall response rate (ORR) to chemotherapy after exposure to …
Management of metastatic cutaneous melanoma: updates in clinical practice
G Schvartsman, P Taranto, IC Glitza… - Therapeutic …, 2019 - journals.sagepub.com
In recent years, several drugs have been approved for the treatment of patients with
metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive …
metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive …
[HTML][HTML] The current treatment landscape of malignant pleural mesothelioma and future directions
B Bertin, M Zugman, G Schvartsman - Cancers, 2023 - mdpi.com
Simple Summary Malignant pleural mesothelioma is an invasive and drug-resistant tumor
related to asbestos exposure, with limited therapy options. It is associated with an …
related to asbestos exposure, with limited therapy options. It is associated with an …
Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma
G Schvartsman, K Perez, G Sood… - Annals of internal …, 2017 - acpjournals.org
Background: Immune checkpoint inhibitors are frequently used to treat patients with
metastatic melanoma. However, all of the clinical trials for these drugs have excluded …
metastatic melanoma. However, all of the clinical trials for these drugs have excluded …
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
G Schvartsman, R Ferrarotto… - … advances in medical …, 2016 - journals.sagepub.com
Lung cancer is the leading cause of cancer death in the United States. The vast majority of
patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5 …
patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5 …
Association between weight gain during adjuvant chemotherapy for early‐stage breast cancer and survival outcomes
G Schvartsman, AM Gutierrez‐Barrera, J Song… - Cancer …, 2017 - Wiley Online Library
Obese and overweight women have an increased risk of breast cancer and worse outcomes
at the time of diagnosis. Women tend to gain weight after breast cancer diagnosis and …
at the time of diagnosis. Women tend to gain weight after breast cancer diagnosis and …
Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease
G Schvartsman, NA Pinto, D Bell, R Ferrarotto - Head & neck, 2019 - Wiley Online Library
Salivary gland cancers represent a rare group of tumors composed by over 20 histological
subtypes. Initially treated as one single disease, its diagnosis, prognosis, and treatment are …
subtypes. Initially treated as one single disease, its diagnosis, prognosis, and treatment are …
[HTML][HTML] Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
G Schvartsman, K Perez, JE Flynn, JN Myers… - … for immunotherapy of …, 2017 - Springer
Background Immunotherapy plays a key role in the treatment of metastatic melanoma.
Patients with autoimmune conditions and/or on immunosuppressive therapy due to …
Patients with autoimmune conditions and/or on immunosuppressive therapy due to …
[HTML][HTML] Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
Regorafenib was approved as third-line therapy for advanced Gastrointestinal Stromal
Tumour (GIST) at a starting dose of 160 mg daily 3 weeks on, 1 week off, based on …
Tumour (GIST) at a starting dose of 160 mg daily 3 weeks on, 1 week off, based on …